The latest Phase 2 trial results of the investigative therapy Pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF) further demonstrated the drug’s therapeutic potential to reduce fibrosis progression and ameliorate IPF clinical manifestations, with no reported adverse toxicity. So concludes an oral presentation, “RAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical…
Phase 2 Results Demonstrate Potential of FibroGen’s Pamrevlumab to Treat IPF
It’s no secret that when you are diagnosed with a chronic illness, your life will inevitably change in numerous ways. Lung diseases, such as idiopathic pulmonary fibrosis (IPF), are bound to impact your physical, mental, and emotional health because breathing is involved in every aspect of our lives.
An inhaled version of miRagen Therapeutics‘ potential fibrosis therapy MRG-201 rendered genes involved in scarring nearly inactive in a rat model of lung fibrosis, the company reported. The preclinical-trial study also showed that most of the compound reached the animals’ lungs. The fact that little of it was found in other tissue…
Scientists at the University of Pennsylvania identified two populations of lung mesenchymal cells that may play a distinct role such in diseases as pulmonary fibrosis — one that seems to protect against disease and the other possibly promoting it when things go awry. Results suggest that future therapies targeting each cell type…
Given the stage of life I am in, many people are curious to know what type of work I do for a living. This curiosity often comes naturally to people when interacting with young adults — especially when they know about the years of schooling that many…
https://www.youtube.com/watch?v=SYssJOKfZ_U A diagnosis of pulmonary fibrosis can be terrifying and confusing and can often take a long time to come to terms with. In this video from EmpowHER, pulmonary fibrosis patient Dyane talks about what she most fears about the disease and how PF has impacted her life. MORE:Â …
The British Lung Foundation has a series of videos featuring idiopathic pulmonary fibrosis (IPF) patients sharing their stories. The patients come from all walks of life and their journeys are all very different. In this video, Joyce explains that it took four years before she received her idiopathic pulmonary fibrosis diagnosis.
Synairgen and Pharmaxis are preparing a Phase 1 clinical trial of PXS-5382A for pulmonary fibrosis and other tissue-scarring disorders. Positive results of preclinical-trial studies on the therapy’s pharmacology — the way it works — and toxicology paved the way for the trial, the company said. PXS-5382A blocks an enzyme known…
Pulmonary fibrosis (PF) is a chronic lung disease where the tissue in the lungs becomes scarred and stiffens over time. Like all diseases, PF does not discriminate and there have been many celebrities who have suffered from the condition. Sadly, some have lost their lives to the disease. According to …
A combination of Ofev (nintedanib) and Esbriet (pirfenidone) is as safe a therapy for idiopathic pulmonary fibrosis as the individual components alone, a Phase 4 clinical trial indicates. Preliminary trial findings also suggested that the combination might be more effective than either therapy alone, although researchers said this needs to…
